Abstract
Immune checkpoint (IC) therapy is the mainstay in the treatment of non-small-cell lung cancer (NSCLC). IC therapy prolonged overall survival (OS) as compared with conventional chemotherapy; however, long-term survival benefits from IC therapy were moderate and limited. IC chemo-combinations highly cost and have high discontinuation rates due to adverse events. A long-term OS of IC monotherapy is very similar to those of IC chemo-combinations. Presently, tumor PD-L1 expression levels/tumor proportion score (TPS) are used as predictive biomarkers of response to IC monotherapy, though the clinical validation and performance are modest.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
